NMDA Antagonist Side Effects: What Troche Users Should Know

What the Research Found

A new clinical analysis published in Psychiatric Times takes a careful look at the side effect profiles and discontinuation rates of NMDA receptor antagonists — the drug class that includes ketamine and esketamine (Spravato) — in patients with treatment-resistant depression (TRD). The review, published April 22, 2026, synthesizes what clinicians are observing in real-world and trial settings: that while NMDA antagonists offer meaningful antidepressant effects, tolerability varies considerably depending on the specific agent, the delivery route, and individual patient factors. Discontinuation — patients stopping treatment early due to side effects or lack of efficacy — remains a clinically significant issue that deserves more systematic attention than it typically receives. Read the original coverage in Psychiatric Times.

Why Delivery Route Matters More Than Most Patients Realize

The core insight buried in this kind of comparative research is one that troche patients often discover firsthand: the way ketamine enters your body shapes the side effect experience as much as the drug itself does. IV ketamine infusions deliver the drug rapidly into the bloodstream, producing intense dissociative effects within minutes — effects that are psychologically significant and require clinical monitoring but resolve quickly as the infusion ends. Intranasal esketamine (Spravato) follows a similarly accelerated absorption curve with its own dissociative and blood pressure profile, and requires in-office administration under observation for two hours post-dose.

Sublingual and buccal troches, by contrast, are absorbed gradually through the oral mucosa over 15–30 minutes before the remainder passes into the GI tract. This slower, lower-peak delivery profile is precisely why troche patients tend to describe their dissociative experiences as gentler and more manageable than what infusion patients report. The plasma peak is blunted. The onset is gradual. For many patients, this means side effects like nausea, dizziness, and perceptual disturbances are present but not overwhelming — and critically, they are experienced at home in a controlled personal environment rather than in a clinical chair.

This matters for discontinuation rates. If a patient finds IV ketamine too intense or logistically difficult to sustain (cost, travel, time off work), they may stop treatment entirely — even if the underlying ketamine is helping. Troches lower that friction considerably. Patients who might discontinue infusion-based protocols sometimes find that troches offer a sustainable long-term maintenance path that keeps them in treatment.

The Side Effects Troche Patients Actually Encounter

Research like this is a useful prompt to review what the real-world troche side effect picture looks like, based on clinical practice patterns in 2026. The most commonly reported effects among sublingual ketamine patients include:

• Dissociation and perceptual changes: Mild to moderate at standard therapeutic doses (typically 100–400 mg depending on protocol). Most patients describe this as a floaty, dreamlike quality rather than the more pronounced altered states reported in higher-dose infusion contexts.
• Nausea: Present in a meaningful minority of patients, particularly early in treatment. Timing the dose — taking it on a light stomach, avoiding dosing immediately after eating — reduces this significantly for most.
• Elevated blood pressure: A known pharmacological effect of ketamine across all delivery routes. Patients with pre-existing hypertension should have this monitored, especially during early titration.
• Cognitive blunting or fatigue: Some patients report next-day grogginess or difficulty concentrating, particularly at higher doses. This is worth tracking in a symptom log and raising with prescribers if persistent.
• Oral discomfort: Troches are held sublingually for absorption. Some formulations have a bitter or medicinal taste, and prolonged contact can cause mild mucosal irritation in sensitive patients. This is formulation-dependent and often addressable by switching flavoring or vehicle.

The side effects that cause the most discontinuation in IV and intranasal settings — overwhelming dissociation, clinic-dependent administration burden, high per-session cost — are largely absent from the troche experience, which is a genuine structural advantage for long-term TRD management.

What This Means for Troche Access and Compounding in 2026

Research that clarifies the side effect and discontinuation landscape for NMDA antagonists serves an important policy function, not just a clinical one. The compounded ketamine troche market exists because it fills a genuine gap: FDA-approved esketamine (Spravato) is expensive, clinic-bound, and logistically demanding, while IV ketamine lacks formal FDA approval for depression and sits outside most insurance coverage. Compounded troches, prescribed off-label and prepared by accredited compounding pharmacies, have become the practical middle path for hundreds of thousands of TRD patients.

As the evidence base for NMDA antagonists matures — including data on which patients discontinue, why, and at what rates — it strengthens the clinical argument for access to flexible, at-home delivery formats. If discontinuation in IV and intranasal protocols is meaningfully driven by tolerability and logistical burden, then troches aren't just a cheaper alternative: they're a clinically meaningful improvement in treatment sustainability for the right patient.

For patients currently on troche protocols, the practical upshot is straightforward: track your side effects systematically, communicate them to your provider, and don't assume that what you read about ketamine side effects in clinical trials necessarily reflects your own experience. The delivery route makes a real difference — and that difference is increasingly something the research community is paying attention to.